Literature DB >> 29250258

How To Manage Oral Anticoagulation Periprocedurally During Ablations And Device Implantations.

Sarah A Worsnick1, Pugazhendhi Vijayaraman1.   

Abstract

More than 150, 000 patients undergo ablation for atrial fibrillation (AF) each year.Current guidelines recommend oral anticoagulation in all patients undergoing AF ablation. A large number of patients undergoing cardiac implantable electronic devices (CIEDs) are on long-term oral anticoagulation. These patients are at increased risk for thromboembolism with interruption of oral anticoagulation. Due to the increased risk for bleeding complications during the procedure combined with the need to prevent thromboembolism, periprocedural management of anticoagulation in these patients can be challenging. In this article we review the current evidence for periprocedural management of oral anticoagulation in patients undergoing ablation and CIED implantation.

Entities:  

Year:  2016        PMID: 29250258      PMCID: PMC5673317          DOI: 10.4022/jafib.1500

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  27 in total

1.  Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  James D Douketis; Alex C Spyropoulos; Frederick A Spencer; Michael Mayr; Amir K Jaffer; Mark H Eckman; Andrew S Dunn; Regina Kunz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Management of antithrombotic therapy in patients undergoing invasive procedures.

Authors:  Todd H Baron; Patrick S Kamath; Robert D McBane
Journal:  N Engl J Med       Date:  2013-05-30       Impact factor: 91.245

3.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

Review 4.  The safety and efficacy of antithrombotic therapy in patients undergoing cardiac rhythm device implantation: a meta-analysis.

Authors:  Xiaowei Yang; Zhongsu Wang; Yong Zhang; Xiangcui Yin; Yinglong Hou
Journal:  Europace       Date:  2015-02-18       Impact factor: 5.214

5.  Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period.

Authors:  Oussama M Wazni; Salwa Beheiry; Tamer Fahmy; Conor Barrett; Steven Hao; Dimpi Patel; Luigi Di Biase; David O Martin; Mohamed Kanj; Mauricio Arruda; Jennifer Cummings; Robert Schweikert; Walid Saliba; Andrea Natale
Journal:  Circulation       Date:  2007-11-12       Impact factor: 29.690

6.  Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy.

Authors:  Uwe K H Wiegand; Dominik LeJeune; Frank Boguschewski; Hendrik Bonnemeier; Frank Eberhardt; Heribert Schunkert; Frank Bode
Journal:  Chest       Date:  2004-10       Impact factor: 9.410

7.  Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation.

Authors:  Gerald V Naccarelli; Riccardo Cappato; Stefan H Hohnloser; Francis E Marchlinski; David J Wilber; Jim Xiang; Changsheng Ma; Susanne Hess; David Wyn Davies; Larry E Fields; Andrea Natale
Journal:  J Interv Card Electrophysiol       Date:  2014-07-09       Impact factor: 1.900

8.  Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.

Authors:  Mohamed Bassiouny; Walid Saliba; John Rickard; Mingyuan Shao; Albert Sey; Mariam Diab; David O Martin; Ayman Hussein; Maurice Khoury; Bernard Abi-Saleh; Samir Alam; Jay Sengupta; P Peter Borek; Bryan Baranowski; Mark Niebauer; Thomas Callahan; Niraj Varma; Mina Chung; Patrick J Tchou; Mohamed Kanj; Thomas Dresing; Bruce D Lindsay; Oussama Wazni
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-04-03

9.  Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.

Authors:  Taishi Kuwahara; Mitsunori Abe; Masaru Yamaki; Hiroyuki Fujieda; Yumiko Abe; Katsushi Hashimoto; Misako Ishiba; Hirotsuka Sakai; Keiichi Hishikari; Masateru Takigawa; Kenji Okubo; Katsumasa Takagi; Yasuaki Tanaka; Jun Nakajima; Atsushi Takahashi
Journal:  J Cardiovasc Electrophysiol       Date:  2016-02-12

10.  The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation - A Brief Summary.

Authors:  Paulus Kirchhof
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-11-29
View more
  1 in total

1.  Predictors of Successful Ultrasound Guided Femoral Vein Cannulation in Electrophysiological Procedures.

Authors:  Francesco De Sensi; Gennaro Miracapillo; Luigi Addonisio; Marco Breschi; Marco Scalese; Alberto Cresti; Francesco Paneni; Ugo Limbruno
Journal:  J Atr Fibrillation       Date:  2018-10-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.